35 results about "Antibody receptor" patented technology

The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

The invention provides a tilted fiber Bragg grating (TFBG)-based surface plasmon resonance (SPR) biosensor which is characterized by comprising a broadband light source (1), a polarizing beam splitter prism (2), an optical isolator (3), a TFBG (4) coated with gold / biological adsorption layer, a reaction tank (5) and a spectrum analyzer (6), wherein the broadband light source (1) and the polarizing beam splitter prism (2) are connected with each other by virtue of an optical fiber and then are connected with the optical isolator (3); and the TFBG (4) coated with the gold / biological adsorption layer is arranged in the reaction tank (5) and is connected with the optical isolator (3) and the spectrum analyzer (6). The TFBG serves as a sensing part, and compared with a common optical fiber SPR sensor, the SPR biosensor disclosed by the invention has the advantages that the wavelength of the light source is simply changed, any mode of emitting light to a fiber core-cladding layer at different angles can be almost generated, resonance is easily realized, the resonance strength is greatly improved, and the information detection capacity is greatly enhanced; the sensitivity of the detector is greatly improved, and the detector can be used for detecting change of concentration of a solution with small biological molecules; and moreover, bovine serum albumin is adopted by the biological adsorption layer, and thus the interaction process between protein-protein and antibody-receptor biological proteins can be efficiently and accurately monitored.

This composition and method provides for a method for reducing GVHD in a human subject which comprises administering to the subject at a predefined interval effective GVHD-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of GVHD. This invention also provides a method for treating a subject with GVHD comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4.sup.+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

Described are methods for treating, preventing, or reducing the risk of, miscarriages, especially recurrent miscarriages. The methods comprise administering to a female subject a therapeutic agent that modulates the activity or binding of components of the complement system, together with a pharmaceutically acceptable carrier. For example, the therapeutic agent can be a C3-convertase inhibitor, an antibody against C5, an antagonist of the C5a receptor, or an antibody against factor B or factor D. Screening methods for agents that can prevent or reduce the risk of miscarriages, especially recurrent miscarriages, are also described.

The invention discloses a method for improving the sensitivity of competitive immunoassay. The method is mainly characterized in that a micromolecular substance to be detected is fully reacted with an antibody / receptor firstly and then reacted with a second molecule which participates in competition and is located on a solid phase in a short time, thus the sensitivity of the competitive immunoassay can be greatly improved. The method disclosed by the invention has the advantages of simplicity in operation, low cost, no need of expensive equipment and professional technicians, high sensitivity, and applicability to a plurality of immunoassay methods.

The in vivo and in vitro use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. The eukaryotic cells include a variety of cell types, e.g. insect, reptile, fish, mammal and tumor cells. The suitable materials for transport include biochemicals such as reporter molecules, antibiotics, biopharmaceuticals and carbohydrates including polysaccharides, lipopolysaccharides, polynucleotides, such as DNA and RNA, and glycoproteins and proteins including antigens, enzymes, antibodies, receptors and hormones. In addition, Invaplex enhances the immune response to DNA vaccines and also can function by itself as a vaccine against shigellosis.

This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

The present invention relates to an antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a particularly well suited antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

The invention relates to a chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR comprises an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system. The invention relates to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid molecule comprising a sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. In one embodiment, the autoantigen encoded by the nucleic acid sequence comprises or consists of an N- methyl-D-aspartate receptor (NMDAR), or one or more NMDAR fragments. The invention further relates to the chimeric autoantibody receptor (CAAR) protein of the invention, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR) of the invention, a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and the use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The in vivo and in vitro use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. The eukaryotic cells include a variety of cell types, e.g. insect, reptile, fish, mammal and tumor cells. The suitable materials for transport include biochemicals such as reporter molecules, antibiotics, biopharmaceuticals and carbohydrates including polysaccharides, lipopolysaccharides, polynucleotides, such as DNA and RNA, and glycoproteins and proteins including antigens, enzymes, antibodies, receptors and hormones. In addition, Invaplex enhances the immune response to DNA vaccines and also can function by itself as a vaccine against shigellosis.

Use of the surface presentation level of binders (e.g., antibodies, receptors) on cultured higher eukaryotic cells in vitro as a predictive indicator of developability characteristics, e.g., solubility, of the binders. Display libraries of higher eukaryotic cells, e.g., mammalian cells, adapted for use in screening surface-displayed binders for developability and affinity of target binding. High-throughput screening of display libraries with in-built selection for developability including binder solubility, capability to be formulated at high concentrations, low propensity for non-specific binding, and half-life. Enrichment of populations of binders for developability characteristics and / or other qualities such as target binding and affinity, by controlling cell surface presentation of binders from an inducible promoter operably linked to binder-encoding DNA.

Use of the surface presentation level of binders (e.g., antibodies, receptors) on cultured higher eukaryotic cells in vitro as a predictive indicator of developability characteristics, e.g., solubility, of the binders. Display libraries of higher eukaryotic cells, e.g., mammalian cells, adapted for use in screening surface-displayed binders for developability and affinity of target binding. High-throughput screening of display libraries with in-built selection for developability including binder solubility, capability to be formulated at high concentrations, low propensity for non-specific binding, and half-life. Enrichment of populations of binders for developability characteristics and / or other qualities such as target binding and affinity, by controlling cell surface presentation of binders from an inducible promoter operably linked to binder-encoding DNA.

The present invention relates to a homogeneous immunoassay method, which comprises at least two detection areas, in one detection area it is judged whether there is a first complex formed by donor-to-be-detected antibody-acceptor, and in another detection area Judging whether there is a second complex formed by donor-antigen-receptor; wherein, the donor can generate singlet oxygen in an excited state, and the acceptor can react with singlet oxygen to produce detectable signal of. The method solves the problem of HOOK effect of high-concentration samples and low detection sensitivity of low-concentration samples in the one-step detection of antigen and antibody. At the same time, the method also solves the problem that the positive result cannot be distinguished from antibody positive or antigen positive in combined detection of antigen and antibody. The method of the present invention is especially suitable for combined detection of HIV antigen and antibody.